Connor, Clark & Lunn Investment Management Ltd. Gritstone Bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$2.46 - $4.75 $263,566 - $508,919	107,141 Added 642.29%	123,822 $318,000
Q2 2022 Aug 05, 2022	BUY	$1.77 - $4.34 $29,525 - $72,395	16,681 New	16,681 $40,000
Q1 2022 May 12, 2022	SELL	$4.03 - $12.19 $526,406 - $1.59 Million	-130,622 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$8.76 - $13.71 $1.14 Million - $1.79 Million	130,622 New	130,622 $1.68 Million
Q3 2021 Nov 12, 2021	SELL	$6.41 - $13.54 $341,153 - $720,625	-53,222 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$8.13 - $10.2 $34,715 - $43,554	4,270 Added 8.72%	53,222 $486,000
Q1 2021 May 13, 2021	BUY	$4.07 - $27.11 $199,234 - $1.33 Million	48,952 New	48,952 $462,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account